| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | CD22 | Synonyms | SIGLEC-2, SIGLEC2 | Type of gene | protein-coding |
| Chromosome | 19 | Map location | 19q13.12 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | CD22 molecule | ||||
| GTO ID | GTC2450 |
| Trial ID | NCT04539444 |
| Disease | Non-Hodgkin's Lymphoma |
| Altered gene | CD19|CD22 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19/CD22 CAR-T cells |
| Co-treatment | Tislelizumab |
| Phase | Phase2 |
| Recruitment status | Unknown |
| Title | A Study of CD19/22 cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma |
| Year | 2020 |
| Country | China |
| Company sponsor | The First Affiliated Hospital of Soochow University |
| Other ID(s) | CCPD-1 in lymphoma |
| Cohort 1 | |||||||||||||||
|
|||||||||||||||